Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.49 |
| ▸ | CSF1R | P07333 | 9/20 | 0.49 |
| ▸ | KDR | P35968 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172465 | 0.87 | PDGFRB (0.62) | ALDH1A1LMNAPDGFRBCSF1RKDR | |
| SCHEMBL2175002 | 0.83 | PDGFRB (0.51) | ALDH1A1LMNAPDGFRBCSF1RKDR | |
| SCHEMBL2177709 | 0.79 | PDGFRB (0.62) | PDGFRBCSF1RKDRFLT3 | |
| SCHEMBL5592064 | 0.72 | MET (0.47) | ALDH1A1LMNAPDGFRBCSF1RKDR | |
| SCHEMBL5598674 | 0.72 | PDGFRB (0.60) | ALDH1A1PDGFRBCSF1RKDRKDM4E | |
| SCHEMBL4371203 | 0.71 | KDM4E (0.51) | ALDH1A1KDM4EHSD17B10TSHRMAPT | |
| SCHEMBL2175292 | 0.71 | PDGFRB (0.63) | ALDH1A1PDGFRBCSF1RKDRKDM4E | |
| SCHEMBL2175177 | 0.70 | PDGFRB (0.61) | ALDH1A1PDGFRBCSF1RKDRKDM4E | |
| SCHEMBL2173413 | 0.69 | PDGFRB (0.62) | ALDH1A1PDGFRBCSF1RKDRKDM4E | |
| SCHEMBL2173834 | 0.68 | EGFR (0.51) | ALDH1A1KDM4EHSD17B10MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| WO-2007113548-A1 | NAPHTHYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | ALDH1A1 887/4885LMNA 1122/4885PDGFRB 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.